Scholars Central

ArticlePublished 17 May 2024

Analysis on Effectiveness, Safety and Blood Lipid Levels of Atorvastatin Calcium with Ezetimibe in Coronary Heart Disease

Authors: Jiangbo Yu, D. L. Zhu, Xiaoli Wang, Z. J. An, J. Y. Zhao

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

This study focuses to find out the influence of atorvastatin calcium with ezetimibe on the effectiveness, safety and blood lipid levels in coronary heart disease. 95 coronary heart disease individuals admitted between April 2020 and April 2023 were selected and were assigned as control (n=45) and research group (n=50). Control group received atorvastatin calcium monotherapy and the research group were given a combination of atorvastatin calcium and ezetimibe. The effectiveness and adverse effects like gastrointestinal reactions, myalgia, loss of appetite and rash were comparatively analyzed. Blood lipid levels (low and high-density lipoprotein cholesterol, total cholesterol and triglyceride) were evaluated. Further, serum inflammatory indices namely, tumor necrosis factor-alpha, interleukin-6 and C-reactive protein were analyzed. Similarly oxidative stress indices (myeloperoxidase, malonyldialdehyde and superoxide dismutase) were compared between both the groups. The research group was found to have an evidently higher total effective rate and a similar incidence of total adverse reactions with the control group. Marked reduction in low density lipoprotein cholesterol, total cholesterol, triglyceride, tumor necrosis factor-alpha, interleukin-6, C-reactive protein, myeloperoxidase and malonyldialdehyde in the research group after treatment was found; while an evident increase in high-density lipoprotein cholesterol and superoxide dismutase were identified, which was higher than the baseline and the control group. Conclusively, atorvastatin calcium plus ezetimibe is effective and safe in treating coronary heart disease, and can significantly ameliorate blood lipid levels, serum inflammatory and oxidative stress indices.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Indian Journal of Pharmaceutical Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalIndian Journal of Pharmaceutical Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Jiangbo Yu”
  • BylineArticles whose byline prints “D. L. Zhu”
  • BylineArticles whose byline prints “Xiaoli Wang”
  • BylineArticles whose byline prints “Z. J. An”
  • BylineArticles whose byline prints “J. Y. Zhao”